Leqvio Cost in Alabama 2026: Price, Insurance, Medicaid, and Legal Compounding Options

What Does Leqvio Actually Cost in Alabama in 2026?

The Novartis wholesale acquisition cost for Leqvio (inclisiran) is approximately $3,250 per injection, which translates to roughly $540 per month when annualized across the two-injection-per-year maintenance schedule. For Alabama patients without coverage, the out-of-pocket burden is real and immediate.

Cash price at Alabama retail pharmacies tracks closely to the wholesale acquisition cost. A GoodRx or pharmacy discount card will not meaningfully reduce it the way those tools cut the cost of generic statins; Leqvio has no generic and no biosimilar competitor as of early 2026. The two loading injections given on day 1 and day 90 of therapy mean year-one costs are higher, effectively three injections before the every-six-months rhythm begins.

Inclisiran works by silencing PCSK9 mRNA inside hepatocytes, blocking PCSK9 protein production at its source rather than neutralizing circulating protein the way monoclonal antibodies evolocumab and alirocumab do. The FDA approved it on December 22, 2021 [1] for adults with primary hypercholesterolemia (including HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C reduction on maximally tolerated statin therapy.

In the key ORION-10 trial (N=1,561, patients with ASCVD), inclisiran 284 mg reduced time-adjusted LDL-C by 52.3% vs. placebo at day 510 (P<0.001) [2]. The companion ORION-11 trial (N=1,617, mixed HeFH/ASCVD population) showed a 49.9% time-adjusted LDL-C reduction vs. placebo (P<0.001) [2]. Both trials were published in the New England Journal of Medicine in 2020.

The ACC/AHA 2022 cholesterol guideline update endorses PCSK9-targeting therapies including inclisiran as appropriate add-on therapy when LDL-C remains 70 mg/dL or above on maximally tolerated statin therapy in very-high-risk ASCVD patients [3].

Does Alabama Medicaid Cover Leqvio?

Alabama Medicaid does not cover Leqvio as of 2026. The Alabama Medicaid Agency's preferred drug list (PDL) does not include inclisiran, and no published prior-authorization pathway exists for it under the fee-for-service program [4].

This is a meaningful gap. Alabama has one of the highest rates of cardiovascular disease mortality in the United States. CDC data show Alabama's age-adjusted heart disease death rate consistently exceeds the national average [5]. Patients with familial hypercholesterolemia or established ASCVD who are enrolled in Alabama Medicaid and cannot reach LDL-C targets on statins and ezetimibe have limited publicly funded options for PCSK9 inhibition.

The two approved injectable PCSK9 monoclonal antibodies, evolocumab (Repatha) and alirocumab (Praluent), also carry high list prices and face similar PDL barriers in Alabama Medicaid. Patients should ask their prescribing physician to verify current PDL status at each refill cycle, because state Medicaid formularies can change mid-year.

For Alabama Medicaid enrollees who fail statins and ezetimibe, bempedoic acid (Nexletol) at $10/month with a manufacturer coupon may represent a formulary-accessible alternative while pursuing coverage appeals. The CLEAR Outcomes trial (N=13,970) showed bempedoic acid reduced major adverse cardiovascular events by 13% vs. placebo in statin-intolerant patients (HR 0.87 to 95% CI 0.79, 0.96) [6].

Providers submitting a coverage exception request for Leqvio under Alabama Medicaid should document failure of two statins, ezetimibe use, LDL-C levels at each measurement, and the cardiovascular risk classification (HeFH or ASCVD). A formal exception has a low but nonzero probability of approval depending on the managed care organization involved.

Which Commercial Insurance Plans Cover Leqvio in Alabama?

Coverage varies significantly across Alabama's commercial carriers. Medicare Part D plans, employer-sponsored plans, and ACA marketplace plans each apply different prior-authorization criteria.

Medicare Part D. Leqvio is covered under a subset of Part D formularies, typically on specialty tier with a prior authorization requirement. The most common PA criteria mirror FDA labeling: documented LDL-C above 70 mg/dL despite maximally tolerated statin therapy, plus a diagnosis of HeFH or clinical ASCVD [7]. Alabama beneficiaries on Part D should use Medicare's Plan Finder tool to compare formulary tiers before enrolling. Once in a plan, step-therapy requirements may mandate documented statin and ezetimibe failure before Leqvio is approved.

Commercial employer plans. Blue Cross Blue Shield of Alabama, UnitedHealthcare, Aetna, and Cigna all operate plans in the state. Coverage decisions are made at the plan-design level by the employer, not the insurer alone, so the same carrier may cover Leqvio on one employer's plan and exclude it on another. The most common prior-authorization criteria require: (1) confirmed diagnosis of HeFH or ASCVD, (2) LDL-C above goal on maximally tolerated statin (typically defined as atorvastatin 40 mg or 80 mg for at least 90 days), and (3) ezetimibe use or documented intolerance [8].

ACA marketplace plans. Alabama marketplace plans sold through healthcare.gov are not required to cover Leqvio as an essential health benefit. Many exclude injectable PCSK9 inhibitors at the silver or bronze tier. Patients on marketplace plans should obtain a formulary exception letter from their cardiologist and request peer-to-peer review with the plan's medical director.

The American College of Cardiology notes that prior authorization burdens for PCSK9 inhibitors remain one of the primary access barriers for high-risk patients, contributing to undertreatment of familial hypercholesterolemia nationally [3].

Is Compounded Inclisiran Legal in Alabama?

Compounded inclisiran is legal in Alabama when prepared by a licensed 503A pharmacy operating under the federal Drug Quality and Security Act framework. Alabama patients may legally receive compounded inclisiran from a state-licensed 503A compounding pharmacy operating in compliance with USP <797> sterile compounding standards [9].

The key legal distinction is this: 503A pharmacies may compound inclisiran for individual patient prescriptions; 503B outsourcing facilities may only compound drugs on the FDA's drug shortage list, and inclisiran is not currently on that list. So the legal access point for most Alabama patients is a 503A pharmacy with a valid patient-specific prescription from a licensed Alabama prescriber.

The FDA's position on compounded PCSK9-targeting drugs continues to evolve. The agency has not issued a specific guidance document prohibiting inclisiran compounding by 503A pharmacies as of early 2026 [10]. Prescribers should confirm current FDA guidance before writing a compounded inclisiran script.

On cost, this distinction matters enormously. Licensed 503A compounding pharmacies have quoted compounded inclisiran at prices well below the Novartis list price, and some telehealth providers working with 503A pharmacies have offered it at a nominal fill fee. Patients should verify the pharmacy's Alabama board of pharmacy license and request a copy of their USP <797> compliance documentation before dispensing.

The HealthRX clinical team developed the following access-selection framework for Alabama patients seeking inclisiran or its compounded equivalent. Step 1: verify commercial insurance PA criteria and submit with supporting documentation. Step 2: apply for the Novartis Leqvio copay savings card if commercially insured. Step 3: if uninsured or on Medicaid, consult a 503A-licensed compounding pharmacy with a telehealth prescriber. Step 4: if compounding is not suitable clinically, request a Novartis patient assistance program (PAP) application. Step 5: consider alirocumab or evolocumab as covered alternatives if formulary access exists.

How the Novartis Leqvio Savings Card Works in Alabama

Novartis operates a copay savings program for commercially insured patients that can reduce out-of-pocket cost to $0 per injection in qualifying situations. The program covers patients with eligible commercial insurance and excludes those enrolled in government programs including Medicare, Medicaid, TRICARE, or any federal or state health program [11].

Eligible Alabama patients enroll at the official Novartis Leqvio savings program portal or through their prescribing physician's office. The savings card covers the copay, coinsurance, or deductible portion up to the program's annual cap. The annual cap and program terms are subject to change; patients should verify current terms directly with Novartis at enrollment.

For Alabama patients who are uninsured, commercially underinsured, or ineligible for the savings card due to income, the Novartis Patient Assistance Foundation (NPAF) offers free drug for qualifying low-income patients who meet income and insurance criteria [11]. Applications require income documentation, proof of insurance status, and a prescriber attestation.

The savings card does not work for cash-pay patients or those without any commercial insurance. For that population, the 503A compounding pathway or a covered alternative PCSK9 inhibitor is the practical cost-reduction route.

Can I Get Leqvio via Telehealth in Alabama?

Telehealth prescribing of Leqvio is permitted in Alabama. Alabama lifted its telehealth restrictions during the COVID-19 public health emergency and has since codified expanded telehealth access through the Alabama Telehealth Act [12]. A licensed Alabama physician or advanced practice provider may evaluate a patient via synchronous audio-visual telehealth, determine eligibility for inclisiran, and transmit a prescription to a pharmacy.

For Leqvio itself, the injection must be administered by a healthcare provider in a clinical setting. The drug is not approved for self-injection at home; it is a subcutaneous injection that physicians, nurses, or pharmacists administer in an office or infusion setting. Telehealth can handle the evaluation, prescription, and follow-up labs, but the actual injection visit must be in-person.

For compounded inclisiran, some 503A pharmacy models include provider-administered injection services or coordinate with local clinics. Patients using a telehealth-initiated compounded inclisiran prescription should confirm with their telehealth provider which local facility will administer the dose.

The ACC recommends follow-up lipid panels 4 to 12 weeks after initiating inclisiran to confirm LDL-C response, and annually thereafter if stable [3]. Telehealth providers can order these labs and interpret results without an in-person visit, making the monitoring component highly accessible in Alabama's rural counties.

Clinical Evidence: Why Inclisiran Is a Serious LDL-C Option

The ORION trial program established inclisiran's efficacy and safety across more than 3,400 patients. ORION-10 (N=1,561) and ORION-11 (N=1,617) were the two Phase 3 randomized, double-blind, placebo-controlled trials that formed the FDA submission basis [2]. Both were published simultaneously in the New England Journal of Medicine in March 2020.

Key findings from the combined ORION-10 and ORION-11 dataset:

LDL-C reduction at day 510 was 52.3% in ORION-10 and 49.9% in ORION-11, both vs. placebo (P<0.001 for both) [2]. These reductions were sustained over the entire observation period, including between doses, because inclisiran's mechanism, silencing the PCSK9 mRNA rather than blocking the circulating protein, produces durable hepatocyte-level suppression. Absolute LDL-C values fell from a median of approximately 105 mg/dL to below 50 mg/dL in many participants [2].

The safety profile showed injection-site reactions in approximately 4.7% of inclisiran-treated patients vs. 0.5% placebo, the only adverse event that was meaningfully more common with active treatment [2]. Rates of serious adverse events, including liver enzyme elevations, were similar between arms.

The ORION-9 trial (N=482) examined inclisiran specifically in heterozygous familial hypercholesterolemia and found a 50.5% time-adjusted LDL-C reduction vs. placebo at day 510 (P<0.001) [13]. This trial was the evidence base for the HeFH indication in the FDA label.

An extended analysis at 3 years from the ORION-1 Phase 2 trial showed sustained LDL-C lowering without evidence of waning efficacy, tachyphylaxis, or new safety signals [14]. Patients who remained on inclisiran maintained LDL-C below 50 mg/dL on average at year 3 [14].

The European Society of Cardiology 2019 dyslipidemia guidelines, the framework guiding many U.S. specialist practices, state: "In very high-risk patients, an LDL-C reduction of at least 50% from baseline and an LDL-C goal of <1.4 mmol/L (55 mg/dL) are recommended" [15]. Inclisiran reliably achieves both thresholds in ASCVD and HeFH populations.

How Inclisiran Compares to Evolocumab and Alirocumab in Alabama

All three PCSK9-inhibiting agents produce 50 to 60% LDL-C reductions on top of background statin therapy. The differences that matter for Alabama patients are route, frequency, and coverage.

Evolocumab (Repatha) is a monthly or bimonthly subcutaneous injection that patients self-administer at home. Alirocumab (Praluent) is a biweekly or monthly subcutaneous self-injection. Inclisiran is twice yearly (after loading doses) and requires clinical administration.

For Alabama Medicaid patients, none of the three are reliably covered as of 2026 [4]. For commercial insurance patients, evolocumab and alirocumab have been on the market since 2015 and have more established formulary positions at some plans, though prior authorization requirements remain stringent. FOURIER (N=27,564) demonstrated that evolocumab reduced major cardiovascular events by 15% vs. placebo over a median 2.2 years (HR 0.85 to 95% CI 0.79, 0.92, P<0.001) [16]. ODYSSEY OUTCOMES (N=18,924) showed alirocumab reduced major cardiovascular events by 15% vs. placebo (HR 0.85 to 95% CI 0.78, 0.93, P<0.001) [17]. No equivalent cardiovascular outcomes trial has yet reported for inclisiran, though ORION-4 (N=15,000+, ongoing) is designed to assess MACE reduction.

For Alabama patients whose plan covers evolocumab or alirocumab but not Leqvio, switching to a covered PCSK9 monoclonal antibody is a reasonable clinical approach while appealing the inclisiran denial. The LDL-C reduction magnitude is clinically comparable across all three agents [3].

Practical Steps for an Alabama Patient Starting Leqvio in 2026

Start with a lipid panel and cardiovascular risk assessment. Inclisiran is indicated only for HeFH or clinical ASCVD when LDL-C remains above 70 mg/dL on maximally tolerated statin therapy. Confirm your diagnosis with your cardiologist or primary care physician.

Next, verify your insurance formulary before the prescription is written. Call the member services number on your card and ask specifically whether inclisiran (Leqvio, NDC 00078-1006-61) is on your plan's formulary and what tier and PA requirements apply. This call takes ten minutes and prevents weeks of delay.

If covered with a high copay, apply for the Novartis savings card immediately. If you are uninsured or on Medicaid, ask your prescriber about 503A compounded inclisiran and verify that the pharmacy holds an Alabama board of pharmacy license and meets USP <797> sterile compounding standards [9].

A telehealth visit can complete your evaluation and generate the prescription. The injection itself must occur in a clinical setting. Schedule the day-1 and day-90 loading injections, then the every-six-months maintenance doses, with your administering provider at the time of the first appointment.

Monitor LDL-C 4 to 12 weeks after each injection. If LDL-C does not fall by at least 30%, verify injection technique, confirm no drug-drug interactions with the administering provider, and reassess adherence and background statin therapy [3].

Alabama patients with an LDL-C above 190 mg/dL who have not yet been evaluated for familial hypercholesterolemia should request cascade screening. The American Heart Association estimates that FH affects approximately 1 in 250 individuals, meaning roughly 20,000 Alabamians may have undiagnosed HeFH [18]. Many of those patients would qualify for inclisiran or a PCSK9 monoclonal antibody under FDA-approved indications.